Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| androgen independent metastatic prostate cancer |
|
IngentaConnect Therapeutic options in androgen-independent Of men with metastatic prostate cancer who undergo androgen ablation, 70â“80% respond Keywords: androgen-independent prostate cancer; PSA; estramustine; androgen independent prostate cancer - Healthcare.com In Patients With Metastatic Androgen Independent Prostate Cancer And Circulating Neuroendocrine Markers Continuous Androgen Deprivation Therapy 23 Phase II study of weekly docetaxel in symptomatic androgen Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer J. Clin. Oncol., January 1, 2003; 21(1): 123 - 128. Vinorelbine, doxorubicin, and prednisone in androgen-independent mustine in androgen-independent metastatic prostate can-. cer: a Phase II study. Cancer. 2000;89:1824â“1828. 13. Sweeney CJ, Monaco FJ, Jung SH, et al. Vinorelbine and estramustine in androgen-independent metastatic metastatic prostate cancer. METHODS. Twenty-five men with androgen-independent metastatic prostate can-. cer were treated with the combination of Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer (January). Punam H Patel PharmD BCPS1 Denise R Kockler PharmD Id-1 expression induces androgen-independent prostate cancer cell Since the majority of late stage prostate cancer is androgen independent, .. specific antigen after hormonal therapy of metastatic prostate cancer. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Metastatic hormone-refractory prostate cancer has a heterogeneous . of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Immunotherapy (APC8015) for Androgen Independent Prostate Cancer Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data Androgen synthesis in castration-adapted metastatic prostate Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic, androgen independent prostate cancer. No presentation available Intermittent chemotherapy in metastatic androgen-independent Intermittent chemotherapy in metastatic androgen-independent prostate cancer T M Beer1, M Garzotto2, W D Henner1, K M Eilers1 and E M Wersinger1 Blackwell Synergy - BJU Int, Volume 100 Issue 3 Page 490-492 Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003; NCI Cancer Bulletin for June 20, 2006 (HTML) - National Cancer Clinical trials have shown that chemotherapy with the drug docetaxel improves the survival of men with metastatic, androgen-independent prostate cancer. Androgen-Independent Prostate Cancer Treated with Resection of the Androgen-Independent Prostate Cancer Treated with Resection of the Solitary Metastatic Site Raj S. Pruthi, J. Slade Hubbard, Erik Kouba, Eric Wallen Low PSA Metastatic Androgenâ“ Independent Prostate Cancer Low PSA Metastatic Androgen- Independent Prostate Cancer A. Sellaa, M. Konichezkyb, D. Flexa, A. Sulkesa, J. Banielc Genitourinary Medical Oncology Unit and Androgen-independent prostate cancer is a heterogeneous group of Androgen-independent prostate cancer is a heterogeneous group of diseases: Metastatic hormone-refractory prostate cancer has a heterogeneous morphology Vinorelbine and estramustine in androgen-independent metastatic METHODS: Twenty-five men with androgen-independent metastatic prostate cancer were treated with the combination of vinorelbine and estramustine. Management of Androgen-Independent Metastatic Prostate Cancer 1 A significant shift in the approach toward managing metastatic androgen-independent prostate cancer (AIPC) occurred last year, when, for the first time, Management of Androgen-Independent Metastatic Prostate Cancer Immunotherapy (APC8015, Provenge(R)) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a |
| androgen independent metastatic prostate cancer |
|
after cancer prostate testosterone therapy doctor in mexico new prostate green laser light prostate surgery best cancer center prostate treatment |